The serotonin-estrogen axis describes the bidirectional relationship between estrogen signaling and serotonin (5-HT) neurotransmission—a neuroendocrine interface that is profoundly modulated by the Gut Microbiome. Estrogen regulates serotonin synthesis (via tryptophan hydroxylase expression), serotonin receptor density (5-HT2A), and serotonin reuptake transporter (SERT) expression.
Conversely, serotonin modulates hypothalamic GnRH pulsatility, affecting estrogen production. The gut microbiome sits at the center of both systems: it controls estrogen recirculation (Estrobolome) and produces ~95% of the body's serotonin via enterochromaffin cell stimulation.
Evidence map3 cited passagesInspect provenance +
Estrobolome → estrogen levels: Gut bacterial beta glucuronidase deconjugates estrogens, increasing circulating free estrogen. dysbiosis alters the estrobolome, disrupting estrogen homeostasis.
PMDD: Abnormal serotonergic sensitivity to estrogen/progesterone fluctuations across the menstrual cycle. The interaction between allopregnanolone (GABA-A modulator), estrogen, and serotonin defines PMDD neurobiology.
Postpartum depression: Precipitous estrogen drop at delivery disrupts the serotonin-estrogen equilibrium. Inflammatory biomarkers (IL-6, TNF-alpha) compound the disruption.
The Microbiome Connection#
Three microbiome pathways converge on this axis:
- Estrobolome → estrogen levels: Gut bacterial Beta-Glucuronidase deconjugates estrogens, increasing circulating free estrogen. Dysbiosis alters the estrobolome, disrupting estrogen homeostasis.[1]Kaliannan et al. 2018 — Estrogen-Mediated Gut Microbiome Alterations Influence Sexual Dimorphism in Metabolic Syndrome in MiceKanakaraju Kaliannan, Ruairi C. Robertson, Kiera Murphy et al. · 2018Open reference 1 ↓
- Tryptophan metabolism → serotonin: The microbiome modulates tryptophan availability for serotonin synthesis. Dysbiosis-driven Metal-Driven Inflammation shunts tryptophan into the Kynurenine Pathway (via IDO/TDO), reducing serotonin precursor availability.
- SCFA → enterochromaffin cells → 5-HT release: Short-chain fatty acids (particularly Butyrate) stimulate enterochromaffin cells to release serotonin. SCFA depletion from dysbiosis reduces peripheral serotonin production.
Clinical Relevance#
PMDD: Abnormal serotonergic sensitivity to estrogen/progesterone fluctuations across the menstrual cycle. The interaction between Allopregnanolone (GABA-A modulator), estrogen, and serotonin defines PMDD neurobiology.[2]Cheng 2025 — Neuroinflammation in PMS and PMDD (Review)Cheng et al. · 2025Open reference 2 ↓[3]Itriyeva 2022 — PMS and PMDD in Adolescents (Review)Khalida Itriyeva · 2022Open reference 3 ↓[4]Nexha 2024 — Biological Rhythms in PMS/PMDD (Systematic Review)Adile Nexha, Luisa Caropreso, Taiane de Azevedo Cardoso et al. · 2024Open reference 4 ↓
Postpartum depression: Precipitous estrogen drop at delivery disrupts the serotonin-estrogen equilibrium. Inflammatory biomarkers (IL-6, TNF-alpha) compound the disruption.[5]Silva-Fernandes 2024 — Inflammatory Biomarkers and Perinatal Depression: A Systematic ReviewAnabela Silva-Fernandes, Ana Conde, Margarida Marques et al. · 2024Open reference 5 ↓
Menopausal depression: Estrogen decline reduces serotonergic tone → increased depression risk. Endometriosis: Estrogen excess (via dysbiotic estrobolome) drives lesion growth while serotonergic disruption drives associated pain and mood symptoms.
Cross-References#
- Serotonin—neurotransmitter page
- Estrobolome—microbial estrogen recirculation (Primitive 7)
- Allopregnanolone—GABA-A modulator in the estrogen-progesterone-serotonin triad
- GABA (Gamma-Aminobutyric Acid)—complementary inhibitory neurotransmitter
- Gut-Brain Axis—broader gut-brain framework
- Tryptophan—serotonin precursor
- Kynurenine Pathway—inflammation-driven tryptophan shunting away from serotonin
- Beta-Glucuronidase—estrogen deconjugation enzyme
References 5
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Kanakaraju Kaliannan, Ruairi C. Robertson, Kiera Murphy et al. (2018). Kaliannan et al. 2018 — Estrogen-Mediated Gut Microbiome Alterations Influence Sexual Dimorphism in Metabolic Syndrome in Mice. Microbiome.
- 2
Cheng et al. (2025). Cheng 2025 — Neuroinflammation in PMS and PMDD (Review). Frontiers in Endocrinology.
- 3
Khalida Itriyeva (2022). Itriyeva 2022 — PMS and PMDD in Adolescents (Review). Current Problems in Pediatric and Adolescent Health Care.
- 4
Adile Nexha, Luisa Caropreso, Taiane de Azevedo Cardoso et al. (2024). Nexha 2024 — Biological Rhythms in PMS/PMDD (Systematic Review). BMC Women's Health.
- 5
Anabela Silva-Fernandes, Ana Conde, Margarida Marques et al. (2024). Silva-Fernandes 2024 — Inflammatory Biomarkers and Perinatal Depression: A Systematic Review. PLOS ONE.
Article network
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Backfill gut microbiome concept links
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
Backfill inflammation concept links
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
Complete corpus-wide Dysbiosis linking
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +52 −0
Inspect exact Git diff ↗